Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -24% Improvement Relative Risk Yeramaneni et al. Remdesivir for COVID-19 LATE Is late treatment with remdesivir beneficial for COVID-19? Retrospective 7,158 patients in the USA (February - May 2020) No significant difference in mortality Yeramaneni et al., Gastroenterology, doi:10.1053/j.gastro.2020.10.011 Favors remdesivir Favors control
Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System
Yeramaneni et al., Gastroenterology, doi:10.1053/j.gastro.2020.10.011
Yeramaneni et al., Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized.., Gastroenterology, doi:10.1053/j.gastro.2020.10.011
Feb 2021   Source   PDF  
  All Studies   Meta
Retrospective 7,158 hospitalized COVID-19 patients in the USA, showing no significant difference in mortality with remdesivir treatment.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 24.0% higher, OR 1.24, p = 0.87, treatment 32, control 7,126, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yeramaneni et al., 28 Feb 2021, retrospective, USA, peer-reviewed, 6 authors, study period 11 February, 2020 - 8 May, 2020.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: Gastroenterology 2021;160:919–921 Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System Samrat Yeramaneni,1 Pratik Doshi,1 Kenneth Sands,2 Mandelin Cooper,2 Dax Kurbegov,1 and Gregg Fromell3 1 Sarah Cannon Research Institute, HCA Healthcare, Nashville, Tennessee; 2Clinical Operations Group, HCA Healthcare, Nashville, Tennessee; 3HCA Research Institute, HCA Healthcare, Nashville, Tennessee P revious reports have found that in-hospital famotidine use in coronavirus disease 2019 (COVID-19) patients was associated with reduced risk of death or intubation.1,2 In 1 of these studies the authors proposed that famotidine inhibits the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) protease, 3-chymotrypsin-like protease, that is essential for breakdown of the immature SARS-CoV-2 protein particles that contribute to the inflammatory response seen in some COVID-19–infected individuals,1 which in turn can lead to acute respiratory distress syndrome, multiorgan dysfunction, physiologic deterioration, and death.3 In a global pandemic with a lack of US Food and Drug Administration–approved targeted therapeutic agents, identification and repurposing of well-established drugs with a proven track record of safety, affordability, and widespread availability are necessary.4 The purpose of this study was to evaluate the reported protective effect of famotidine on mortality in hospitalized COVID-19 patients. Methods Refer to Supplementary Methods for complete details. In brief, admitted adults to affiliated hospitals who tested positive for SARS-CoV-2 by reverse transcriptase polymerase chain reaction between February 11, 2020 and May 8, 2020 were included. Exclusion criteria were death or intubation within 48 hours of admission or if famotidine was received >24 hours after admission. The primary outcome was 30-day all-cause mortality. Primary exposure was in-hospital famotidine use, regardless of dose and route, within 24 hours of admission. To mitigate bias from nonrandomized assignment of treatment, a coarsened exact matching (CEM)5 technique was used for famotidine users and nonusers on age (by 10-year intervals), sex, race, ethnicity, body mass index, comorbidities, and in-hospital hydroxychloroquine (HCQ) use. A multivariable logistic regression model within the CEM cohort and adjusted for baseline World Health Organization (WHO) severity and use of other medications was performed to evaluate the association between famotidine use and 30-day mortality. Results A total of 8915 patients were assessed for eligibility. Of these, 1441 patients (16.2%) were excluded because of death (1.4%), intubation (5.0%), or famotidine >24 hours after admission (9.8%). Of the 7474 eligible patients, 316 patients were excluded for missing discharge disposition status (0.9%) or >30-day mortality (3.4%), resulting in a final sample of 7158 patients. Of the 7158 patients included in the analysis, 1127 patients (15.7%) were exposed and 6031 patients (84.3%) were unexposed. After CEM of the 1156 patients, 410 patients (35.5%) were exposed and 746 patients (64.5%) were unexposed (Supplementary Figure 1). Prematch and Postmatch Characteristics Overall, 15.7% of patients (n ¼ 1127) received famotidine and 84.3% (n ¼ 6031) did not. Mean age was 57.9 ± 19.3 years, 50.9% were women, 44.6% white, and 25.2% black. Famotidine was used for a median of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop